NUTEX Stock Overview
NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally.
+ 1 more risk
NUTEX Investments Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||Ft9.46|
|52 Week High||Ft22.85|
|52 Week Low||Ft8.60|
|1 Month Change||0.21%|
|3 Month Change||-15.91%|
|1 Year Change||-56.10%|
|3 Year Change||-67.93%|
|5 Year Change||-87.55%|
|Change since IPO||-99.96%|
Recent News & Updates
|NUTEX||HU Pharmaceuticals||HU Market|
Return vs Industry: NUTEX underperformed the Hungarian Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: NUTEX underperformed the Hungarian Market which returned -22.9% over the past year.
|NUTEX Average Weekly Movement||6.8%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||4.8%|
|10% most volatile stocks in HU Market||8.4%|
|10% least volatile stocks in HU Market||3.0%|
Stable Share Price: NUTEX is more volatile than 75% of Hungarian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NUTEX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Hungarian stocks.
About the Company
NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally. The company was formerly known as HUMET Trade, Research and Development Public Limited Company and changed its name to NUTEX Investments Public Limited Company in February 2011. NUTEX Investments Public Limited Company is based in Budapest, Hungary.
NUTEX Investments Fundamentals Summary
|NUTEX fundamental statistics|
Is NUTEX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NUTEX income statement (TTM)|
|Cost of Revenue||Ft0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.22|
|Net Profit Margin||-7,204.67%|
How did NUTEX perform over the long term?See historical performance and comparison
Is NUTEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NUTEX?
Other financial metrics that can be useful for relative valuation.
|What is NUTEX's n/a Ratio?|
Price to Book Ratio vs Peers
How does NUTEX's PB Ratio compare to its peers?
|NUTEX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
575 Endurance RP
ROSE Instituto Rosenbusch
524314 Gujarat Terce Laboratories
524632 Shukra Pharmaceuticals
NUTEX NUTEX Investments
Price-To-Book vs Peers: NUTEX is good value based on its Price-To-Book Ratio (0.3x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does NUTEX's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Book vs Industry: NUTEX is good value based on its Price-To-Book Ratio (0.3x) compared to the European Pharmaceuticals industry average (2.2x)
Price to Book Ratio vs Fair Ratio
What is NUTEX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NUTEX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NUTEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NUTEX (HUF9.46) is trading below our estimate of fair value (HUF57.65)
Significantly Below Fair Value: NUTEX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is NUTEX Investments forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NUTEX Investments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether NUTEX Investments is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- NUTEX Investments competitive advantages and company strategy can generally be found in its financial reports archived here.
How has NUTEX Investments performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NUTEX is currently unprofitable.
Growing Profit Margin: NUTEX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NUTEX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NUTEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUTEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.3%).
Return on Equity
High ROE: NUTEX has a negative Return on Equity (-0.7%), as it is currently unprofitable.
Discover strong past performing companies
How is NUTEX Investments's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NUTEX's short term assets (HUF3.8B) exceed its short term liabilities (HUF2.4M).
Long Term Liabilities: NUTEX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NUTEX is debt free.
Reducing Debt: NUTEX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if NUTEX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NUTEX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is NUTEX Investments's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NUTEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NUTEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NUTEX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NUTEX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: NUTEX is not paying a notable dividend for the Hungarian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NUTEX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Gábor Csereklei serves as Chief Executive Officer for Investor Relations at NUTEX Investments Public Limited Company.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.5%.
NUTEX Investments Public Limited Company's employee growth, exchange listings and data sources
- Name: NUTEX Investments Public Limited Company
- Ticker: NUTEX
- Exchange: BUSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Ft1.401b
- Shares outstanding: 148.11m
- Website: https://www.nutex.hu
- NUTEX Investments Public Limited Company
- Telepes u. 53
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.